Three-year Study on Copaxone
Three-year Study Shows Good Efficacy and Safety for Copaxone in MS: Presented at ECTRIMS
Neural Stem Cells Are Long-Lived
Neural Stem Cells Are Long-Lived
trial of the tolerability of Rebif
A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
Mikol D, Lopez-Bresnahan M, Taraskiewicz S, Chang P, Rangnow J; Rebiject Study Group.
Department of Neurology, Multiple Sclerosis Center, University of Michigan, Ann Arbor, MI 48109-0588, USA. dmiko@umich.edu
Injection site reactions (ISRs) are a common side effect of subcutaneous interferon beta therapy, particularly during initiation of therapy… read more »
trial of an energy conservation course for persons with MS
Randomized controlled trial of an energy conservation course for persons with multiple sclerosis.
Mathiowetz VG, Finlayson ML, Matuska KM, Chen HY, Luo P.
Program in Occupational Therapy, University of Minnesota, MMC 388, 420 Delaware St. SE, Minneapolis, MN 55455, USA. mathi003@umn.edu
OBJECTIVE: To assess the short-term efficacy and effectiveness of a six-week energy conservation course on fatigue impact, quality of life and self-efficacy for persons with multiple sclerosis (MS)… read more »
employment status changes in individuals with MS
Factors related to employment status changes in individuals with multiple sclerosis.
Smith MM, Arnett PA.
Psychology Department, Penn State University, 522 Bruce V. Moore Bldg., College of the Liberal Arts, University Park, PA 16802-3105, USA.
In a sample of 50 individuals with multiple sclerosis (MS), participants able to work full-time (‘W’), those who reduced their hours (‘CB’) and those who were unemployed (‘NW’) were compared on demographic and disease variables… read more »
copaxone – new study
Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.
Ruggieri M, Avolio C, Scacco S, Pica C, Lia A, Zimatore GB, Papa S, Livrea P, Trojano M.
Dept. of Neurological and Psychiatric Sciences, University of Bari, Policlinico, Piazza Giulio Cesare, 70124, Bari, Italy, mruggieri@neurol.uniba.it.
Apoptotic deletion of autoreactive T-cells is defective in patients with multiple sclerosis (MS). Glatiramer acetate… read more »
Study on oral drug for RRMS show good benefits and tolerability
FTY720
Phase II 12-month data show sustained benefits and good tolerability in patients with relapsing multiple sclerosis
Basel, October 1, 2005 – Data from the extension of a Phase II study of 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of patients with relapsing multiple sclerosis (MS). The data, presented at the ECTRIMS/ACTRIMS[1] meeting in Thessalonica, Greece, showed that both of the patient groups taking FTY720
Multiple Sclerosis Quality-of-Life
Multiple Sclerosis Quality-of-Life Principles Set Forth Internationally: Presented at ECTRIMS
By Bruce Sylvester THESSALONIKI, GREECE — September 30, 2005 –
Leaders in the field of multiple sclerosis (MS) and its treatment have developed a set of international principles to promote the quality of life of people with the disease. The principles were presented here at the 21[st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on September
The association between cognitive impairment and physical disability in MS
The association between cognitive impairment and physical disability in multiple sclerosis.
BACKGROUND:
The association between cognitive impairment and physical disability was examined in a larger, more representative sample of patients with multiple sclerosis (MS) than in previous studies.
METHOD:
Two hundred and fifty-three patients attending an MS clinic were assessed with respect to physical disability using the Expanded Disability Status Scale and cognitive impairment using a battery of neuropsychological tests.
RESULTS:
Physical disability correlated with duration… read more »
Molecule Linked disorder could lead to treatments for MS
Molecule May Drive Multiple Sclerosis Linked Disorder – Discovery could lead to treatments for transverse myelitis and MS
Researchers report that a single molecule called IL-6 is the cause
of transverse myelitis (TM), an autoimmune disease in
the central nervous system that’s related to multiple sclerosis.
The study found that levels of IL-6 are dramatically elevated in
the spinal fluid of people with TM. The finding may help in the
development of treatments for… read more »
